Effect of Fibrinogen Prophylaxis on Perioperative Bleeding in patients with Cerebral Meningioma undergoing elective Craniotomy: A Double-Blind Placebo-Controlled Randomized Trial

开始日期2022-10-01

申办/合作机构-

CTRI/2020/08/027288 / Not yet recruitingN/AIIT

Use of liquid fibrinogen as gel coating on dental implant surface to enhance osseointegration - A prospective randomized clinical trial

开始日期2020-10-01

申办/合作机构-

100 项与 Fibrinogen (Liminal BioSciences) 相关的临床结果

登录后查看更多信息

100 项与 Fibrinogen (Liminal BioSciences) 相关的转化医学

登录后查看更多信息

100 项与 Fibrinogen (Liminal BioSciences) 相关的专利（医药）

登录后查看更多信息

项与 Fibrinogen (Liminal BioSciences) 相关的文献（医药）

2024-11-01·Physical Biology

Variability in individual native fibrin fiber mechanics

Article

作者: Helms, Christine Carlisle

AbstractFibrin fibers are important structural elements in blood coagulation. They form a mesh network that acts as a scaffold and imparts mechanical strength to the clot. A review of published work measuring the mechanics of fibrin fibers reveals a range of values for fiber extensibility. This study investigates fibrinogen concentration as a variable responsible for variability in fibrin mechanics. It expands previous work to describe the modulus, strain hardening, extensibility, and the force required for fiber failure when fibers are formed with different fibrinogen concentrations using lateral force atomic force microscopy. Analysis of the mechanical properties showed fibers formed from 1 mg ml−1 and 2 mg ml−1 fibrinogen had significantly different mechanical properties. To help clarify our findings we developed two behavior profiles to describe individual fiber mechanics. The first describes a fiber with low initial modulus and high extensible, that undergoes significant strain hardening, and has moderate strength. Most fibers formed with 1 mg ml−1 fibrinogen had this behavior profile. The second profile describes a fiber with a high initial modulus, minimal strain hardening, high strength, and low extensibility. Most fibrin fibers formed with 2 mg ml−1 fibrinogen were described by this second profile. In conclusion, we see a range of behaviors from fibers formed from native fibrinogen molecules but various fibrinogen concentrations. Potential differences in fiber formation are investigated with SEM. It is likely this range of behaviors also occurs in vivo. Understanding the variability in mechanical properties could contribute to a deeper understanding of pathophysiology of coagulative disorders.

2024-11-01·Journal of Pediatric Surgery

A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery

Article

作者: Jenovari, Zoltan ; James, Michael K. ; Mondou, Elsa ; Balanescu, Laura ; Bozzo, Jordi ; Kalinova, Krasimira ; Camprubí, Sandra ; Sharif, Khalid ; Ninov, Borislav ; Camprubí, Sandra ; Mikickovic, Maja ; Vajda, Péter ; Querolt, Montse ; Sretenović, Aleksandar ; Gajdobranski, Djordje ; Mondou, Elsa ; Slavkovic, Andjelka ; Simeonov, Simeon ; Hanna, Kim ; Hanna, Kim ; Irtan, Sabine ; Querolt, Montse ; Kamenov, Krasimir ; Wiener, Isodoro

BACKGROUNDIn this study, two fibrin sealant products, Fibrin Sealant Grifols (FS Grifols 80 mg/mL fibrinogen; 500 IU/mL thrombin) and Evicel (fibrinogen 55-85 mg/mL; thrombin 800-1200 IU/mL) were studied for efficacy in achieving hemostasis at a targeted bleeding site (TBS) on parenchymous or soft tissue in pediatric surgeries.METHODSThis phase 3, single-blind, active comparator, non-inferiority trial compared the number of patients achieving hemostasis at a TBS at four (T₄ - primary endpoint), seven (T₇) and 10 (T₁₀) minutes after application, Safety and tolerability were assessed by recording adverse events during and after procedures. Eligible patients were <18 years old undergoing elective, open, non-cardiac thoracic, abdominal or pelvic surgeries. Preterm (<37 weeks gestation) and newborn (0-27 days) infants were eligible.RESULTSAt T₄, 98.7% of FS Grifols group (n = 91) and 95.4% of the Evicel group (n = 87) achieved hemostasis. All patients with residual bleeding at T₄ were undergoing soft tissue surgery. All patients achieved hemostasis by T₇. At T₁₀, all patients achieved hemostasis except one (FS Grifols (no observation recorded)). There were no incidents of persistent bleeding. For FS Grifols, 26.5% of patients had treatment-emergent adverse events (TEAEs) and 18.4% for Evicel. One TEAE (moderate procedural pain - FS Grifols group) was considered possibly related to study treatment. Three patients died for reasons unrelated to the study medications.CONCLUSIONSFS Grifols was safe and effective at achieving hemostasis in pediatric patients having parenchymous or soft tissue surgeries. The efficacy of FS Grifols was non-inferior to Evicel.LEVEL OF EVIDENCEI.

2024-11-01·Journal of the Mechanical Behavior of Biomedical Materials

Tuning viscoelasticity and stiffness in bioprinted hydrogels for enhanced 3D cell culture: A multi-scale mechanical analysis

Article

作者: Pragnere, Sarah ; Dubreuil, Frédéric ; Errazuriz-Cerda, Elisabeth ; Courtial, Edwin-Joffrey ; Petiot, Emma ; Pailler-Mattei, Cyril ; Marquette, Christophe

Bioprinted hydrogels are extensively studied to provide an artificial matrix for 3D cell culture. The success of bioprinting hydrogels relies on fine-tuning their rheology and composition to achieve shear-thinning behavior. However, a challenge arises from the limited viscoelastic and stiffness range accessible from a single hydrogel formulation. Nevertheless, hydrogel mechanical properties are recognized as essential cues influencing cell phenotype, migration, and differentiation. Thus, it is crucial to develop a system to easily modulate bioprinted hydrogels' mechanical behaviors. In this work, we modulated the viscoelastic properties and stiffness of bioprinted hydrogels composed of fibrinogen, alginate, and gelatin by tuning the crosslinking bath solution. Various concentrations of calcium ionically crosslinked alginate, while transglutaminase crosslinked gelatin. Subsequently, we characterized the mechanical behavior of our bioprinted hydrogels from the nanoscale to the macroscale. This approach enabled the production of diverse bioprinted constructs, either with similar elastic behavior but different elastic moduli or with similar elastic moduli but different viscoelastic behavior from the same hydrogel formulation. Culturing fibroblasts in the hydrogels for 33 days revealed a preference for cell growth and matrix secretion in the viscoelastic hydrogels. This work demonstrates the suitability of the method to decouple the effects of material mechanical from biochemical composition cues on 3D cultured cells.

项与 Fibrinogen (Liminal BioSciences) 相关的新闻（医药）

2024-06-07

·医药笔记

Ventyx大跌38%：公布NLRP3减肥临床前数据

▎Armstrong 2024年6月5日，Ventyx Biosciences公布NLRP3抑制剂用于减重的临床前研究数据。在DIO小鼠模型中，VTX3232减轻体重，减少进食，同时观察到肝脏脂肪和甘油三酯下降，与司美格鲁肽联用表现出更好的效果。消息发布后，Ventyx Biosciences昨日股价大跌38%，目前市值仅剩下2.3亿美元。 VTX3232为一款可以通过血脑屏障的NLRP3抑制剂。 VTX3232可以减少DIO小鼠的炎症因子，包括IL-1β、IL-5、Fibrinogen等。 VTX3232具有一定的减重效果，但相比司美格鲁肽差距较大，与司美格鲁肽联用减重效果有一定提升。抗炎症方面同样不及司美格鲁肽，但联用后效果有一定提升。总结 Ventyx Biosciences计划今年下半年启动VTX3232的2a期临床试验。资本市场对于VTX3232的数据反应比较消极，考虑到其抗炎、减重效果均明显不如司美格鲁肽，这种反应也在情理之中。减重新药研发已经非常激烈，除了司美格鲁肽，Amylin联用、双靶点、三靶点、小分子都已经进入商业化或后期临床阶段，这种情况下VTX3232的临床前数据确实很难对后续临床数据有太高的预期。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床2期

100 项与 Fibrinogen (Liminal BioSciences) 相关的药物交易

登录后查看更多信息